Quality standard
Quality statement 4: Imaging
Quality statement 4: Imaging
Quality statement
People with peripheral arterial disease (PAD) being considered for revascularisation who need further imaging after a duplex ultrasound are offered magnetic resonance angiography (MRA).
Rationale
Imaging should only be performed in people with PAD if it is likely to provide information that will influence their management. Duplex ultrasound followed by MRA, where clinically appropriate and if needed, offers the most accurate, safe and cost-effective imaging strategy for people with PAD. However, local training and expertise and the availability of imaging equipment may be variable.
Quality measures
Structure
(a) Evidence of local arrangements to ensure that healthcare practitioners undertaking imaging are appropriately trained in the use of duplex ultrasound and MRA for PAD.
Data source: Local data collection.
(b) Evidence of local arrangements to ensure that people with PAD being considered for revascularisation who need further imaging after a duplex ultrasound are offered MRA.
Data source: Local data collection.
Process
Proportion of people with PAD being considered for revascularisation needing further imaging after a duplex ultrasound who receive MRA.
Numerator: the number of people in the denominator receiving MRA.
Denominator: the number of people with PAD being considered for revascularisation who need further imaging after a duplex ultrasound.
Data source: Local data collection.
What the quality statement means for different audiences
Service providers ensure that imaging equipment is adequately available, and that people with PAD who are being considered for revascularisation and need further imaging after a duplex ultrasound are offered MRA.
Healthcare practitioners ensure that they offer MRA to people with PAD who are being considered for revascularisation who need further imaging after a duplex ultrasound imaging.
Commissioners ensure that they commission services with adequate availability of imaging equipment and which offer MRA to people with PAD being considered for revascularisation who need further imaging after a duplex ultrasound.
People with peripheral arterial disease whose healthcare practitioner thinks surgery might help to improve their blood flow, are offered imaging tests (for example, an ultrasound) to see whether surgery would be suitable.
Source guidance
Peripheral arterial disease: diagnosis and management. NICE guideline CG147 (2012, updated 2020), recommendations 1.4.1, 1.4.2 and 1.4.3
Definitions of terms used in this quality statement
Revascularisation
Any procedure that is used to restore blood flow to an area of the body that is supplied by narrowed or blocked arteries. This can be done either by making the narrowed arteries wider (angioplasty, stenting), or by using another blood vessel to bypass the blocked or narrowed artery (bypass surgery).
[Adapted from NICE's guideline on peripheral arterial disease, information for the public]
People being considered for revascularisation
This includes people:
-
with intermittent claudication, who should be offered angioplasty only when:
-
advice on the benefits of modifying risk factors has been reinforced (see recommendation 1.2.1 in NICE's guideline on peripheral arterial diseaseand
-
a supervised exercise programme has not led to a satisfactory improvement in symptoms and
-
imaging has confirmed that angioplasty is suitable for the person
-
-
being considered for primary stent placement, for treating people with intermittent claudication caused by complete aorto-iliac occlusion (rather than stenosis)
-
with critical limb ischaemia who need revascularisation, who should be offered angioplasty or bypass surgery, taking into account factors including:
-
comorbidities
-
pattern of disease
-
availability of a vein for grafting
-
patient preference
-
-
being considered for primary stent placement, for treating people with critical limb ischaemia caused by complete aorto-iliac occlusion (rather than stenosis).
[Adapted from NICE's guideline on peripheral arterial disease, recommendations 1.5.3, 1.5.5, 1.6.2 and 1.6.4]